top of page
  • Jef Feeley

Pfizer Agrees to Settle More than 10,000 Zantac Cancer Suits

In case you missed it, Pfizer has agreed to settle more than 10,000 cases that accused it of hiding the cancer risks of Zantac (ranitidine).

Zantac was available as an over-the-counter antacid in the US until April 2020 when it was recalled. The concern was that NDMA, a potential carcinogen was found in some ranitidine.

But before you get too worried, a large-scale study of nearly 1.2 million people in 2023 found that people who took Zantac for at least a month were no more likely to develop cancer than people who took similar drugs such as Pepcid (famotidine).

0 views0 comments


bottom of page